Holen Sie sich die Stockscreener-App
3.805
3.18%
-0.125
Handel nachbörslich:
3.81
0.005
+0.13%
Schlusskurs vom Vortag:
$3.93
Offen:
$3.89
24-Stunden-Volumen:
124.08K
Relative Volume:
0.35
Marktkapitalisierung:
$181.14M
Einnahmen:
$114.70K
Nettoeinkommen (Verlust:
$-37.06M
KGV:
-0.9529
EPS:
-3.9929
Netto-Cashflow:
$-30.69M
1W Leistung:
-7.87%
1M Leistung:
-4.40%
6M Leistung:
+67.62%
1J Leistung:
+123.82%
1-Tages-Spanne:
$3.73
$4.1112
1-Wochen-Bereich:
$3.73
$4.19
52-Wochen-Spanne:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Firmenname
Sab Biotherapeutics Inc
Sektor
Branche
Telefon
305-845-2813
Adresse
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.805 | 187.09M | 114.70K | -37.06M | -30.69M | -3.9929 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-10-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten
SABS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
Valuation Update: Is SAB Biotherapeutics Inc a cyclical or defensive stock2025 Sector Review & Verified Stock Trade Ideas - baoquankhu1.vn
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf - MarketBeat
Geopolitics Watch: Should I buy SAB Biotherapeutics Inc stock nowJuly 2025 Update & Accurate Trade Setup Notifications - baoquankhu1.vn
SABS Should I Buy - Intellectia AI
Stock Report: What chart patterns are forming on SAB Biotherapeutics Inc Equity WarrantJuly 2025 Drop Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Entry Recap: What makes SAB Biotherapeutics Inc Equity Warrant stock attractive today2025 Price Targets & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
RTW INVESTMENTS, LP Acquires Significant Stake in SAB Biotherape - GuruFocus
RTW INVESTMENTS, LP Acquires Significant Stake in SAB Biotherapeutics Inc - GuruFocus
Is SAB Biotherapeutics Inc. a turnaround storyWeekly Profit Recap & Proven Capital Preservation Methods - mfd.ru
Will SAB Biotherapeutics Inc. stock maintain momentum in 2025Weekly Investment Report & Entry Point Confirmation Alerts - mfd.ru
Will SAB Biotherapeutics Inc. stock remain a Wall Street favoriteAnalyst Downgrade & Real-Time Market Trend Scan - mfd.ru
Stock Market Recap: Can YHNAR outperform in the next rallyOil Prices & Weekly Setup with ROI Potential - baoquankhu1.vn
RTW discloses 3.2% SAB Biotherapeutics (SABS) position in 13G/A - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 24.7% - MarketBeat
SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026 - MarketBeat
Will SAB Biotherapeutics Inc. stock recover after earningsEarnings Miss & Short-Term Trading Opportunity Alerts - mfd.ru
What’s the profit margin of SAB Biotherapeutics Inc. Equity WarrantJuly 2025 Catalysts & Real-Time Buy Zone Alerts - mfd.ru
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 6.6%Here's What Happened - MarketBeat
Will SAB Biotherapeutics Inc. outperform small cap indexesJuly 2025 Summary & Accurate Intraday Trading Signals - mfd.ru
Aug Momentum: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantTrade Entry Summary & Risk Controlled Daily Plans - baoquankhu1.vn
SAB Biotherapeutics, Inc. Management to Participate in February Investor Conferences - Quiver Quantitative
Biotech firm SAB Biotherapeutics joins fireside chats at 2 Feb. investor events - Stock Titan
Published on: 2026-01-31 17:26:58 - baoquankhu1.vn
Can SAB Biotherapeutics Inc. weather a recessionJuly 2025 Price Swings & Long-Term Safe Return Strategies - mfd.ru
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in SAB Biothe - GuruFocus
SAB Biotherapeutics Shares Jump 33% After Securing $175M in Oversubscribed Private Placement - MSN
Aug Patterns: Whats HTGCs historical return2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
Insider Sell: Is SAB Biotherapeutics Inc a cyclical or defensive stockQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Investment Review: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantQuarterly Risk Review & High Conviction Investment Ideas - baoquankhu1.vn
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Mood: Is SAB Biotherapeutics Inc Equity Warrant stock undervalued right nowJuly 2025 Earnings & Low Drawdown Trading Techniques - baoquankhu1.vn
SAB Biotherapeutics phase 1 trial of SAB-142 met primary endpoint - MSN
HB Wealth Management LLC Buys New Stake in SAB Biotherapeutics, Inc. $SABS - MarketBeat
Portfolio Update: Will SAB Biotherapeutics Inc. Equity Warrant stock continue upward momentumTrend Reversal & Growth Focused Entry Point Reports - Bộ Nội Vụ
Published on: 2026-01-13 04:34:13 - Улправда
SAB Biotherapeutics, Inc. Updates on SAB-142 Development - TradingView
SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades SAB Biotherapeutics (NASDAQ:SABS) to "Strong-Buy" - MarketBeat
Cash per share of SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap – NASDAQ:SABSW - TradingView — Track All Markets
Will SAB Biotherapeutics Inc. stock continue dividend increasesJuly 2025 Levels & Daily Profit Focused Stock Screening - Улправда
Why SAB Biotherapeutics Inc. stock remains on buy listsJuly 2025 Movers & Verified Momentum Stock Watchlist - Улправда
Will SAB Biotherapeutics Inc. stock see insider buying2025 Earnings Impact & Risk Adjusted Buy and Sell Alerts - Улправда
Is SAB Biotherapeutics Inc. stock a buy on dipsMarket Growth Summary & High Accuracy Swing Entry Alerts - ulpravda.ru
Why SAB Biotherapeutics Inc. stock attracts global investorsQuarterly Market Review & Detailed Earnings Play Strategies - Улправда
Why SAB Biotherapeutics Inc. Equity Warrant stock is recommended by analystsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Los Angeles Daily NewsSAB Biotherapeutics, Inc.Common Stock (Nasdaq:SABS) Stock Quote - FinancialContent
Published on: 2026-01-07 16:05:26 - bollywoodhelpline.com
UBS Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation - Nasdaq
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sab Biotherapeutics Inc-Aktie (SABS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
4.07%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):